Obermatt
See Similar Stocks →

Novavax

NSQ:NVAX · US6700024010
BiotechnologyMedium

360

23
Profit price88
Owner Earnings Yield1
Dividend Yield1
Price/Sales43
EV / Gross Profit81
Price/Book85
Returns on capital96
EBIT Margin75
Gross Profitability63
Accruals39
Owner Earnings Margin69
Sales growth1
Profit Growth30
Long-Term EPS Growth1
Reinvestment79
Price momentum48
Debt load5
Refinancing6
Debt Payback1
Liquidity69
Analyst ratings12
Opinion Changes50
Price Target Upside42
Market mood32
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Novavax doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1987
Employees923
Websitenovavax.com/?locale=US
ISINUS6700024010
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyInfectious DiseasesVaccinesBiopharmaBiotechnologyHealth CarePharmaceutical

Description

Novavax, Inc. (Novavax), together with its wholly owned subsidiaries, operates as a biotechnology company. The company’s growth strategy focuses on maximizing the impact of its cutting-edge technology by forging partnerships for its Matrix-M adjuvan…

Analysis

Middle-of-the-road

Novavax, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
16
2026

All-time high

33

Mar 2026

All-time low

16

Jun 2026

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
43
—
—
—
Price/Earnings
85
—
—
—
Price/Book
85
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
92
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Novavax with its peers
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Tarsus Pharmaceuticals
NSQ:TARS
29
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Maravai LifeSciences Holdings
NSQ:MRVI
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →